<DOC>
	<DOCNO>NCT02412020</DOCNO>
	<brief_summary>This double-blind , randomize , placebo-controlled , 2-period crossover , 2-cohort study adult patient refractory chronic cough . The purpose study assess efficacy safety inhale PA101 deliver via eFlow high efficiency nebulizer treat refractory chronic cough .</brief_summary>
	<brief_title>Treatment Refractory Chronic Cough With PA101</brief_title>
	<detailed_description>The study consist 2 treatment cohort refractory chronic cough : Idiopathic Pulmonary Fibrosis ( IPF , Cohort 1 ) Chronic Idiopathic Cough ( CIC , Cohort 2 ) . In cohort , study include two treatment period 14 day separate Washout Period 14 day Period 1 Period 2 . The two period identical except Period 2 , patient crossover alternate treatment receive Period 1 , accord 1:1 randomization scheme . During period , patient self-administer study drug ( i.e. , 40 mg PA101 Placebo PA101 via eFlow ) three time daily 14 consecutive day period . Objective cough count record 24-hour period use cough count device ( Leicester Cough Monitor ) Baseline , Day 7 Day 14 treatment period . In IPF cohort , patient allow use antifibrotic therapy ( i.e. , pirfenidone , nintedanib , N-acetylcysteine ) course study provide dose stabilize least 3 month prior Screening throughout study period . Clinical safety assessment perform start end treatment period .</detailed_description>
	<mesh_term>Cough</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<criteria>Diagnosis Idiopathic Pulmonary Fibrosis ( base presence definitive possible usual interstitial pneumonia UIP pattern highresolution compute tomography exclude lung disease associate environmental occupational exposure , connective tissue disease drug ; transfer capacity carbon monoxide correct hemoglobin [ TLCOc ] &gt; 25 % predict within 12 month Screening ; force vital capacity [ FRC ] &gt; 50 % predict within 1 month Screening ) Chronic Idiopathic Cough ( unresponsive target treatment identify underlying trigger include postnasal drip , asthmatic/nonasthmatic eosinophilic bronchitis , gastroesophageal reflux disease ) Refractory chronic cough least 8 week Daytime cough severity score &gt; 40 mm Cough Severity VAS Screening Daytime average cough count â‰¥15 per hour Screening Willing able provide write informed consent Current recent history clinically significant medical condition , laboratory abnormality illness could put patient risk compromise quality study data determine investigator Upper low respiratory tract infection within 4 week Screening History malignancy treat untreated within past 5 year , exception localize basal cell carcinoma cervix carcinoma situ Current recent history ( within 12 month ) excessive use abuse alcohol Current recent history ( within 12 month ) abuse legal drug use illegal drug substance Participation investigational drug study within 4 week Screening Use prednisone , narcotic antitussive , baclofen , gabapentin , inhaled corticosteroid , benzonatate , dextromethorphan , carbetapentane , H1 antihistamine , leukotriene modifier , cromolyn sodium within 2 week Screening Pregnant breastfeeding female , childbearing potential unwilling practice acceptable mean birth control abstinence study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>